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Mounting evidence links cancers possessing stem-like properties with worse prognosis. Network biology
with signal processing mechanics was explored here using expression profiles of a panel of tumor stem-like
cells (TSLCs). The profiles were compared to their parental tumor cells (PTCs) and the human embryonic
stem cells (hESCs), for the identification of gene chromobox homolog 5, CBX5, as a potential target for lung
cancer. CBX5was found to regulate the stem-like properties of lungTSLCs andwas predictive of lung cancer
prognosis. The investigation was facilitated by finding target genes based on modeling epistatic signaling
mechanics via a predictive and scalable network-based survival model. Topologically-weighted
measurements of CBX5were synchronized with those of BIRC5, DNMT1, E2F1, ESR1,MLH1,MSH2, RB1,
SMAD1 and TAF5. We validated our findings in another Taiwanese lung cancer cohort, as well as in
knockdown experiments using sh-CBX5 RNAi both in vitro and in vivo.
I
t has been long understood that cancer results from sequentially evolving genetic events. In solid tumors,
malignancies are viewed as a collection of diseases that are heterogeneous in nature in: genomics, transcrip-
tomic variations, and clinical outcomes. Lately, evidence has supported the claim that cancers possessing
stem-like properties typically have a worse prognosis1,2. Other studies showed that overexpression of epithelial-
mesenchymal transition transcription factors enhanced stem-like properties and increased the aggressiveness of
tumor cells3–5. We established several panels of tumor stem-like cells (TSLCs) in head and neck2,6, brain7, and
breast8. Here, we focus on lung adenocarcinomas (LACs), for which we have established a panel of lung TSLCs
previously aswell9. Indeed, lung cancer is one of the leading causes of cancer-related deaths worldwide10. Its highly
invasive and metastatic phenotypes are the major reasons for treatment failure and poor prognosis11.
The study aim is to identify a critical target regulating both lung cancer survival and the stem-like properties of
lung TSLCs. Lately, epigenetic regulators such as chromatin modifiers and polycomb group proteins were shown
to be important players in cell fate decisions and reprogramming12. Nuclear perturbation was also known to play
an important role in cancer biology13. Given the noisy and scarce nature of TSLCs, we first try to consolidate a
consensus gene signature of low variation and consistent gene activities across the panel of TSLCs of different
tissue of origins. Such gene signature is important that it could distinguish TSLCs from the parental tumor cells
(PTCs) and from the human embryonic stem cells (hESCs). In this study, enriched signaling pathways of DNA
methylation and establishment and/ormaintenance of chromatin architecture were found in the consensus TSLC
networks generated by the consensus gene signature. Base on the lung TSLC-specific gene signature, we further
built the lung TSLC network model for survival prediction. CBX5, a chromatin regulator in the polycomb group,
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was identified as a significant target in lung cancer survival analysis
through a scalable network-based target identification process.
Importantly, we verified that CBX5 was also essential for the main-
tenance of aggressiveness and stem-like properties in lung TSLCs.
We believe that our work supports a stronger claim of the epigenetic
roadmap for the future understanding of lung cancer and lung
TSLCs.
Our network models are derived from gene expression signature
given the tumor stem-like states. Topologically-weighted signal
mechanics incorporated in the networkmodel are designed to dissect
a possible role of functional noise. Several lines of evidence showed
that stochastic fluctuations in gene expression were observed in
embryonic stem cells leading to different lineages and cell fates14–16.
Researchers also tried integration of electrical potentials in neurons
and the brain functional magnetic resonance images17 in relational
network-based models to understand noisy signals. Therefore, we
propose such network-based topologically-weighted signal model
to estimate individual cancer survival time.
In summary, network-based models based on the TSLC panels
were developed in this work to help understand the underlying bio-
logical perturbation leading to the variable survival time of lung
cancer patients. It was expected that such network-based models
could further elucidate the regulatory mechanisms leading to tumor
invasion and metastasis. Data is available at GEO GSE35603. The R
codes for all analysis could be accessed at https://sites.google.com/
site/nwtoposignalincancer/.
Results
From our previous experiences working on TSLCs, we have found
that the panels of TSLCs were quite heterogeneous depending on the
experimental cultivation procedures and/or the original tumor sam-
ples. In addition, due to the scarce nature of TSLCs, it was difficult to
have a comprehensive transcriptome of TSLCs within a single tumor
type. In this study, we therefore first aimed at establishing the sound-
ness and importance of commonality across the panel of TSLCs. We
then proceeded to develop an application model for lung cancer
survivals based on the common and consistent gene expression pro-
files in lung CD1331- TSLCs.
Characterization of lung TSLCs. Recent studies showed that
expression of CD133 in lung cancers represents high tumorigenicity
and resistance to cytotoxic therapy18,19. We previously reported greater
chemoradioresistance of CD1331-TSLCs isolated from non-small cell
lung cancers (NSCLCs) compared to CD1332-NSCLCs9. Here, we
isolated CD1331-TSLCs from 7 NSCLCs (Fig. 1a). Isolated lung
CD1331-TSLCs could form floating spheroid-like bodies in serum-
free medium more easily than CD1332-NSCLCs. Quantitative RT-
PCR results showed a higher level of transcripts of stemness genes
(Oct4, Sox2, and Nanog) and drug resistant genes (MDR1, ABCG2) in
lung CD1331-TSLCs (Fig. 1b). Lung CD1331-TSLCs displayed not
only higher invasion activity, as well as enhanced foci formation, but
also resistance to cisplatin, doxorubicin, and taxol (Fig. 1c–e). In vivo,
transplants of lung CD1331-TSLCs exhibited more aggressiveness
tumorigenity in the lungs (Table 1).
Distinct transcriptional patterns of the inter-modular hubs of the
consensus TSLC networks. First, we performed differential
expression analysis between panels of TSLCs vs. PTCs for each
tumor tissue type or experimental technique to come up with eight
gene lists. These lists are of similar length, setting the 87.5% of
absolute value of fold changes as the filtering threshold, merged as
geneset A (Fig. S1, Table S1). Second, we ranked the top 500 probes
with minimal transcriptional variability within TSLCs. A nonre-
dundant geneset B consisting of 459 probes of low transcriptional
variability in TSLCs as well as geneset A was summarized. Third, we
filtered out gene signatures with inconsistent activities of TSLCs
comparing to PTCs to be the concordant geneset C. We identified
a consensus gene-list of 64 probes characterized with low variation
and commonality (lv_com). They were found not only having con-
cordant gene activities in at least two tumor types/experimental
conditions, but also either differentially expressed in at least two
tumor types/conditions (n518) or with minimal transcriptional
variation in TSLCs (n546). In clustering analysis, consensus gene
signature of lv_com demonstrated its capability of best separation
across the three panels of cells. Hierarchical clustering and non-
metric multi-dimensional scaling of TSLCs, PTCs, and hESCs
based on lv_com were displayed in Fig S2. By using lv_com as
inputs in the Ingenuity Pathways Analysis (IPA), DNA methy-
lation and transcriptional repression signaling pathways were
found significantly enriched (Fisher exact test, 2log(P-value)54.17).
The output literature networks were merged with human protein-
protein interactions (PPIs). We consolidated links in the merged
networks by setting threshold of gene-gene co-expression within
TSLCs. There are 77 links co-expressed among all TSLCs with
abs(Pearson Correlation Coefficients; PCCs) .0.4 out of the total
161 links in the merged networks(Fig. S3; Table S2&3). PCCs of 77
links were mostly positive with the maximum of 0.92 between
HNRNPD and ILF3. There are 49 genes, topologically categorized
as 12 inter-modular hubs, 22 intra-modular hubs, and 15 periphery
genes, in the consensus TSLCs networks. Of note, in the group of
inter-modular hubs, averaged gene activities (Exprs) and SNR of
TSLCs were statistically different from those of hESCs or those of
PTCs (Fig. S2). DNMT3A was the only gene that distinguished three
panels (Fig. S4). Gene Ontology (GO) functional annotation revealed
differences in the biological processes characterized by these two
different kinds of hubs (Table 2). Intra-modular hubs were all
membrane bound intracellular organelles and 43% of them parti-
cipated in the establishment and/or maintenance of chromatin
architecture. All of the inter-modular hubs had molecular function
of protein binding.
Network signaling in lung-TSLC networks. There are 96 genes - 25
inter-modular hubs, 44 intra-modular hubs, and 27 periphery genes -
and 144 links in the lung-TSLC networks (Fig. S5; Table S4&5).
Network-based survival analyses were conducted using two
different sets of member genes, i.e. hub genes only (Nj569) or all
genes in the lung-TSLC networks (Nj596), as well as using different
combination of weights and weighting genes (Ni): (1) intra-modular
hubs weighted by degrees; (2) inter-modular hubs weighted by
degrees; (3) inter-modular hubs weighted by focality; (4) intra- and
inter-modular hubs weighted by degrees; and (5) intra-modular hubs
weighted by degrees plus inter-modular hubs weighted by focality.
We calculated the measurements of Exprs,wt.Exprs,Mag, Spec, and
SNR derived from each combinatory network model (Ni vs. Nj) and
tested them in the survival analyses. By grouping lung cancer patients
into quartiles given the network-based measurements, we found that
at least one type of measurement could significantly rank patients
into 2 to 4 risk groups (Table S6). To eliminate the possibility of the
sample size in each dataset being too small, we further conducted
meta-analyses with the pooled metastasis-free survivals (MFS;
n5374) and overall survivals (OS; n5828). Exprs values of inter-
modular hubs were consistently significant predictors of OS and
MFS. With regard to the MFS, measurements of Exprs, wt.Exprs,
Spec, and SNR of both the intra- and inter-modular hubs
demonstrated trend-like significance (Table S6). We speculated
that the lung-TSLC network model might be more sensitive to
tumor progression.
Identifying a regulatory role of CBX5 in lung-TSLC networks
modulating variation of lung cancer survivals. To identify
potential targets in the lung-TSLC networks, we tried out each
single gene as the weighting gene in the survival analyses (Ni51;
Nj569). Network-based measurements were calculated and first
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 584 | DOI: 10.1038/srep00584 2
tested by survival analyses based on quartiles, and then tested by
linear model fit with survival times. Genes showing statistical
significance in multiple tests were identified into 3 groups: (1) OS-
related; MLH1 and SMAD1; (2) MFS-related; CBX5, CPSF1,
DNMT1, HNF1, IRS1, KPNA2, MSH2, and RASA1; and (3) OS/
MFS-related; CDC2, COL18A1, RACGAP1, and SHC1.
CBX5 was chosen as a target for further validation for its poten-
tial role in lung cancer survival as well as in lung TSLCs based on
the MFS analyses using the public lung cancer transcriptome.
Foremost, levels of Exprs, Spec, and SNR of CBX5 in quartiles
were all significantly demonstrating dosage-like effects. Moreover,
levels of Exprs and SNR of CBX5 were significantly correlated
with the MFS survival time in the metastasis-free group
(Fig. 2a–c). In addition, a general linear model fit existed between
Spec of CBX5 and the reciprocal of MFS time in the metastasis
group (Fig. 2b). It is worthy to note that CBX5 was originally
found differentially expressed in TSLCs of atypical teratoid/rhab-
doid tumor (AT/RT-TSLCs) and consistently induced in lung-
TSLCs. The topological characteristics of CBX5 in the network
models might provide a possible explanation of its role in
TSLCs. CBX5 was an intra-modular hub connected with RB1
and E2F1 in the lung-TSLC networks as well as an inter-modular
hub connected with DNMT3A in the consensus TSLC networks.
In order to determine whether CBX5 participated in lung tumor-
igenesis, we examined the levels of CBX5 in 20 pairs of LAC samples
(T) vs. the corresponding controls (N) by qRT-PCR analysis. RNA
transcripts ofCBX5were significantly higher in the tumor samples as
well as in the metastatic lesions (Fig. 2d). We further collected
another Taiwanese validation cohort of LAC patients for immuno-
histochemical staining (Table S7). The results supported that the
CBX5-positive LAC cases were associated with worse overall survi-
vals (Fig. 2e).
Validation of CBX5 in regulating self-renewal of lung TSLCs.We
tried to verify the significance of CBX5 in the tumorigenicity
and invasiveness of lung cancers by sh-RNAi knockdown of CBX5
in lung TSLCs (Fig. 3a). We showed that the capabilities of
sphere formation, colony formation, and migration/invasiveness of
CD1331-TSLCs treated by sh-CBX5 RNAi were indeed sig-
nificantly inhibited (Fig. 3b–d). Additionally, the percentages of
CD1331-TSLCs and side population (SP) cells treated by sh-CBX5
RNAi were dramatically decreased (Fig. 3e–g).
In order to understand the gene-gene interplays of CBX5 in lung-
TSLC networks, we calculated the pair-wise correlations between
levels of Exprs, Mag, Spec, and SNR of CBX5 with those of the
survival significant genes using the lung cancer transcriptome. We
Figure 1 | Characterization of lung TSLCs. (a) Lung CD1331-TSLCs were sorted and characterized by FACS assay and cultured in bFGF and EGF with
DMEM serum-freemedium. (b) The relativemRNA levels ofOct4, Sox2,Nanog,MDR1, andABCG2weremeasured for the PTCs, CD1332-NSCLCs, and
lung CD1331-TSLCs. (c–e) Evaluation of the cell viability under treatment of cisplatin, doxorubicin, and taxol for the PTCs, CD1332-NSCLCs, and lung
CD1331-TSLCs. (*P , 0.05) All results shown are means of three independent experiments 6 SD. Samples were isolated from No.1 patient listed in
Table 1.
www.nature.com/scientificreports
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found that CBX5 was significantly correlated with the survival signifi-
cant genes such as BIRC5 and DNMT1 among the metastasis-free
patients. The correlations between the Spec or SNR levels were higher
than those of the Exprs orMag. These results indicated that gene-gene
regulatory controls were indeed synchronized under such a network-
based model, especially when taking into account gene membership,
network topology, as well as signal stochasticity. We further tried to
experimentally validate the identified correlated synchronization
between CBX5 vs. the survival significant genes using in vitro sh-
CBX5 RNAi inhibition in lung CD1331-TSLCs. Using RT-PCR, we
detected decreased mRNA expression levels of BIRC5, DNMT1, E2F1,
ESR1,MLH1, MSH2, RB1, SMAD1, SIN3A and TAF5 and in the lung
CD1331-TSLCs treated with sh-CBX5 RNAi (Fig. 3h). Our results
suggested that knockdown of CBX5 in lung-TSLCs could simulta-
neously inhibit these correlated survival significant genes.
Validation of CBX5 in modulating tumorigenicity and aggres-
siveness of lung carcinoma in vivo. In vivo models were utilized
to further examine the effect of sh-CBX5 RNAi knockdown. By
injecting 23105 sh-CBX5 RNAi treated lung CD1331-TSLCs vs.
sh-Luc controls through tail vein after 8 weeks, we demonstrated
that the tumorigenic engraftment, tumor growth rate (Fig. 4a), and
metastatic tendency to lung by lungCD1331-TSLCs (Fig. 4b&c) were
prominently blocked by sh-CBX5 RNAi knockdown. For lung
cancers, surgery is the current standard of care treatment. How-
ever, for locally advanced lung tumors (stage 3b or above) that
cannot be surgically removed, treatment with combined radiation
and chemotherapy would be given to improve survivals. Therefore,
given the aggressive nature of lung CD1331-TSLCs, we further tested
to show that treatment of sh-CBX5 RNAi significantly increased the
radiosensitivity of CD1331-TSLCs in vitro as well (Fig. 4d). Mice
Table 1 | Characterization of tumorigenicity and effects of sh-CBX5 RNAi in lung CD1331-TSLCs from 7 non-small cell lung cancer
(NSCLC) patient
NSCLC
Case
Age/Sex/
Type/Stage CD1331 (%)
Spheres
Formation
Number of cells injected (Number of animals having tumor/Total of 3 animals in each experiment)
CD1331
CD1331
sh-RNA vector
CD1331
sh-CBX5
CD1331
IR-4 Gy
CD1331 sh-CBX5
& IR 4 Gy CD1332
1 82/M/AD/IIIa 7.1 Yes 1,000 (3/3) 1,000 (2/3) 1,000 (0/3) 1,000 (2/3) 1,000 (0/3) 1,000 (0/3)
3,000 (3/3) 3,000 (3/3) 3,000 (0/3) 3,000 (2/3) 3,000 (0/3) 3,000 (0/3)
10,000 (3/3) 10,000 (3/3) 10,000 (1/3) 10,000 (2/3) 10,000 (0/3) 10,000 (0/3)
2 59/F/AD/IIb 4.8 Yes 1,000 (2/3) 1,000 (1/3) 1,000 (0/3) 1,000 (1/3) 1,000 (0/3) 1,000 (0/3)
3,000 (1/3) 3,000 (1/3) 3,000 (0/3) 3,000 (2/3) 3,000 (0/3) 3,000 (0/3)
10,000 (3/3) 10,000 (3/3) 10,000 (2/3) 10,000 (2/3) 10,000 (1/3) 10,000 (0/3)
3 63/F/AD/IIb 3.6 Yes 1,000 (1/3) 1,000 (1/3) 1,000 (0/3) 1,000 (1/3) 1,000 (0/3) 1,000 (0/3)
3,000 (2/3) 3,000 (1/3) 3,000 (0/3) 3,000 (1/3) 3,000 (0/3) 3,000 (0/3)
10,000 (2/3) 10,000 (2/3) 10,000 (1/3) 10,000 (2/3) 10,000 (0/3) 10,000 (0/3)
4 70/M/SC/IIb 11.2 Yes 1,000 (3/3) 1,000 (3/3) 1,000 (0/3) 1,000 (0/3) 1,000 (0/3) 1,000 (0/3)
3,000 (3/3) 3,000 (3/3) 3,000 (1/3) 3,000 (0/3) 3,000 (0/3) 3,000 (0/3)
10,000 (3/3) 10,000 (3/3) 10,000 (3/3) 10,000 (2/3) 10,000 (0/3) 10,000 (0/3)
5 75/M/AD/IIa 3.9 Yes 1,000 (1/3) 1,000 (2/3) 1,000 (0/3) 1,000 (0/3) 1,000 (0/3) 1,000 (0/3)
3,000 (2/3) 3,000 (1/3) 3,000 (0/3) 3,000 (1/3) 3,000 (0/3) 3,000 (0/3)
10,000 (2/3) 10,000 (2/3) 10,000 (1/3) 10,000 (2/3) 10,000 (0/3) 10,000 (0/3)
6 67/M/AD/IIb 15.5 Yes 1,000 (3/3) 1,000 (3/3) 1,000 (0/3) 1,000 (0/3) 1,000 (0/3) 1,000 (0/3)
3,000 (3/3) 3,000 (2/3) 3,000 (1/3) 3,000 (3/3) 3,000 (0/3) 3,000 (0/3)
10,000 (3/3) 10,000 (3/3) 10,000 (2/3) 10,000 (3/3) 10,000 (1/3) 10,000 (1/3)
7 68/M/SC/Ib 2.3 Yes 1,000 (0/3) 1,000 (0/3) 1,000 (0/3) 1,000 (0/3) 1,000 (0/3) 1,000 (0/3)
3,000 (1/3) 3,000 (1/3) 3,000 (0/3) 3,000 (1/3) 3,000 (0/3) 3,000 (0/3)
10,000 (2/3) 10,000 (1/3) 10,000 (1/3) 10,000 (2/3) 10,000 (0/3) 10,000 (0/3)
NSCLC: non-small cell lung carcinoma. Tumor types- AD: lung adenocarcinoma; SC: lung squamous cell carcinoma. Tumor grade/stage: TMN staging.
sh-CBX5 & IR 4 Gy: combined sh-CBX5 RNAi with IR (4Gy) treatment. Cells were transplanted into NOD-SCID mice through the tail vein.
After 8 weeks of transplantation, the tumorigenic ability of tumor-bearing NOD-SCID mice was measured by histological survey in the whole lung.
Table 2 | GeneOntology Functional Enrichment Annotation of consensus TSLC network genes with different gene grouping according to the
topological characteristics
Gene grouping GO Category GO Term % P-Value
All genes BP GO:0006355,regulation of transcription, DNA-dependent 46% 1.8E-06
BP GO:0042981,regulation of apoptosis 27% 4.0E-08
CC GO:0031981,nuclear lumen 25% 2.9E-06
BP GO:0006325,establishment and/or maintenance of chromatin architecture 21% 3.2E-07
Inter-modular hubs MF GO:0005515,protein binding 100% 8.1E-05
BP GO:0043170,macromolecule metabolic process 83% 0.02
BP GO:0048731,system development 42% 0.03
BP GO:0006468,protein amino acid phosphorylation 33% 0.01
Intra-modular hubs CC GO:0043231,intracellular membrane-bound organelle 100% 1.3E-07
BP GO:0043170,macromolecule metabolic process 95% 6.4E-06
BP GO:0050794,regulation of cellular process 90% 1.8E-08
BP GO:0006355,regulation of transcription, DNA-dependent 71% 9.2E-08
BP GO:0006325,establishment and/or maintenance of chromatin architecture 43% 2.9E-09
www.nature.com/scientificreports
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Figure 2 | Network-topologically-based measurements of CBX5 in lung-TSLC network model modulated variability of lung cancer survivals. (a–c)
MFS analyses of quartile groups ofExprs, Spec, and SNR ofCBX5. Xy plots with general linearmodel (GLM) fits forExprs and SNR ofCBX5 vs.MFS time.
Xy plots withGLM fit for Spec ofCBX5 vs. the reciprocal ofMFS time.Metastasis patients colored red andmetastasis-free yellow. (*P, 0.05) (d) Levels of
CBX5mRNA by quantitative real-time PCR from 20 pairs of primary LAC vs. adjacent non-tumorous lung tissues. Levels of CBX5mRNA between local
lung vs. metastatic lesions of 10 patient-pairs were also shown. Results are means of 3 independent experiments 6 SD. (e) Representative results of
immunohistochemical staining forCBX5 in LAC patients at different grades (left, low-grade; right, high-grade). Overall survival analysis according to the
CBX5 expression levels in 125 Taiwanese LAC patients.
www.nature.com/scientificreports
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transplanted with the sh-CBX5 RNAi-treated lung-TSLCs had
significantly prolonged survivals as well (data not shown).
Discussion
We have identified CBX5 as a potential target regulating lung cancer
survivals and the stem-like properties of lung CD1331-TSLCs.
Moreover, interplays of CBX5 with other genes in the lung-TSLC
networkmodel were statistically tested and experimentally validated.
Lung cancer patients of higher CBX5 gene activities were of poorer
prognosis and the knockdown of CBX5 with sh-RNAi in lung
CD1331-TSLCs demonstrated lessened aggressiveness in vivo. We
demonstrated that a scalable and predictable target identification
approach was feasible, given the context of network topology and
signaling mechanics.
CBX5, a highly conserved nonhistone protein containing chro-
matin organization modifier domain, i.e. chromodomain, belongs
to the heterochromatin protein family20. In rodent and D. melano-
gaster cells, CBX5 was found to interact with H3K9me3 or coloca-
lized with H3K9me to the heterochromatin regions21. The role of
heterochromatin in transcriptional gene silencing and long-range
chromatin interactions has been well-established. However, inmam-
malian cells,CBX5 andH3K9mewere found to associate with coding
regions of activated genes, although the possible mechanism was
unclear. Evidence also showed that CBX5 served as a common gene
Figure 3 | Knockdown of CBX5 with sh-RNAi in vitro. (a) Western blot of knockdown of CBX5 in lung CD1331-TSLCs derived from two patients
(No.1&2). The abilities of (b) sphere formation, (c) colony formation, and (d) migration in CD1331-TSLCs treated with sh-CBX5 RNAi were decreased.
The percentages of (e–f) CD1331-TSLCs and (g) SP cells were significantly reduced. (h) Using RT-PCR, we measured suppression of expression levels of
BIRC5, SMAD1, MSH2, DNMT1, E2F1, RB1, TAF5, ESR1, MLH1, and SIN3A in the sh-CBX5 RNAi treated lung CD1331-TSLCs. These genes were
identified by statistically significant correlation with CBX5 in lung cancer survival analysis. All data shown are the mean 6 SD of 3 experiments. (*P, 0.05)
www.nature.com/scientificreports
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expression signature shared by human mature oocytes and embry-
onic stem cells22. Recently, Wong and colleagues identified that
ATRX working together with H3.3 and CBX5 might be a key regu-
lator of ES-cell telomere chromatin23. Here, CBX5 was identified in
both the consensus TSLC and the lung-TSLC network models. Our
findings further supported a recent finding24 that CBX5was essential
in themaintenance of leukemia stem cells (LSCs). To date, we are the
first to reportCBX5 playing an essential role in the regulatory control
of lung-TSLCs, as well as in malignant lung carcinomas. Survival
significant genes identified from our analysis, specifically the iden-
tified target gene CBX5, again highlighted the importance of epige-
netic regulatory controls. Thus, the lung-TSLC network model
provided a link between experimentally cultivated lung-TSLCs and
clinical lung cancer survival times, with statistical significance and
mechanistic understandings.
Recent works by Bro¨ske and colleagues demonstrated the indis-
pensability of DNMT1 for the cell-autonomous survival of hemato-
poietic stem cells (HSCs) and LSCs25. De novo methylation by
DNMT3A and DNTM3B was also shown essential for HSCs renewal
but not for differentiation26. Our findings of DNMT3A in the TSLC-
consensus network, and DNMT1 synchronized with CBX5 in the
lung-TSLC networks, were compatible to the above-mentioned
reports.We recognized that the networkmodels were built on known
gene interactions and knowledge. Nevertheless, high co-expression
in TSLCs lent a better support of their validity. PCC demonstrating
co-expression of DNMT1 with E2F1 was 0.98 and with BIRC5 0.87;
and PCC of DNMT3A with CBX5 was 0.72, with EED 0.62, and with
MYC 0.48, respectively. Collectively, we supported and extended the
importance of epigenetic regulations of TSLCs. However, it remains
an open question in fully understanding the underlying regulation.
Network-based survival models have been developed for breast
cancer27 and glioblastoma28. We are the first to address the stochastic
gene expression activities embedded in biological networks by sum-
marizing them in the noise-like Spec, as well as SNR, in malignant
lung carcinomas. This approach provides each patient a unique esti-
mated profile to summarize the variable transcriptional signature
within the same set of genes in a network model. In conclusion, we
demonstrated that stochastic element of transcriptional profiles of
lung cancers, given the relational model based on the lung-TSLC
networks, could be useful in estimating the prognostic survival
time. Last, the methodology is generic and future exploitation in
other research areas will establish the validity of its robustness and
applicability.
Methods
Microarray data. (1) PTCs and TSLCs: The cultivated TSLCs were of six tissue of
origins: breast, lung, colon, head and neck, glioblastoma, and AT/RT, whose parental
cells wereMCF7, A549, SW480 andHT29, FaDu and SAS, PT1 (primary culture) and
Figure 4 | Inhibition of CBX5 lessened tumorigenicity and aggressiveness of lung TSLCs in vivo. 23105 lung CD1331-TSLCs treated with sh-CBX5
RNAi or sh-Luc controls were injected through tail vein of NOD-SCID mice (n56 per group). The animals were sacrificed and examined 8 weeks after
injection. (a) Tumor volume and (b) the number of metastatic foci (arrows) in the lungs were analyzed by ex vivo GFP imaging and histological
examination. (c) The effects of IR of 2, 4, 6, 8, and 10 Gy were evaluated in CD1331-TSLCs treated with sh-Luc or sh-CBX5 RNAi. Data shown are the
mean 6 SD of 3 experiments. (d) Knockdown of CBX5 in lung CD1331-TSLCs effectively reduced the number of lung metastases in transplanted mice.
Treatment of sh-CBX5 RNAi combined with 4 Gy IR further enhanced the anti-tumor efficacy (*P ,0.05).
www.nature.com/scientificreports
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U87, ATRT, BT, BT6, and BT12, respectively. TSLCs were cultivated by methods
described elsewhere2,3,6–9. For lung TSLCs, we isolated CD1331-TSLCs from tissue
samples of NSCLC patients using the magnetic bead method of FACS assay. We
extracted and purified total RNA according to procedures published elsewhere2. RNA
was hybridized on microarrays of Affymetrix GeneChip HG-U133 plus 2.0 at the
genomic core facilities at the National Yang-Ming University Genome Research
Center. (2) hESCs: Oocytes (GSE12034, N53) and human embryonic stem cells
(hESCs) microarrays were downloaded from the Gene Expression Omnibus (GEO) of
NCBI (GSE7879: VUB01, N53; SA01, N53; and Sheff4 hESCs, N53. GSE9440: T3ES,
N53. H1 hESCs, N54, fromGSE9196 and GSE9510. H9 hESCs, N56, fromGSE9196,
GSE9510, and GSE9940). Please see Table S1 for details. Gene expression data of all
three panels could be downloaded from GEO GSE35603. (3) Lung cancer
transcriptome: Eight datasets with lung cancer survivals were downloaded from GEO
and supplements as described29–32.
A precompiled gene set. A gene list was compiled (5812 GeneIDs) to incorporate
properties of migration33,34, stemness1,35, calcium-related processes36, and cancer-
specific transcript variants37,38 for gene expression analysis.
Gene expression analysis. Please see Fig. S1 for the analysis flow chart. All CEL files
were pre-processed and standardized with mean of zero and SD of 1. We used R/
Bioconductor software for the analysis. Differential gene expression analysis was
controlled for FDR,0.0539, and set with threshold of fold changes of TSLCs vs. PTCs,
to generate geneset A. Coefficient of variance40 was calculated to rank the top 500
probes of lowest transcriptional variability in TSLCs. We combined geneset A and
low variability gene signatures (as geneset B) and further excluded those gene
signatures with inconsistent activities of TSLCs comparing to PTCs (as geneset C).
Among gene signatures with concordant gene activities in at least two tumor types/
experimental conditions, we identified the first list of 64 probes, either differentially
expressed in at least two tumor types/experimental conditions or from the low
variability genes in TSLCs, denoted as a consensus gene-list characterized with low
varation and commonality (lv_com). From geneset C, we found the second list of 145
probes (including 14 probes from lv_com) with consistent gene activities in lung
TSLCs comparing to those of lung PTCs.
Network construction from literature knowledge base, human protein-protein
interactions (PPIs), and co-expression profiles of cultivated TSLCs. Literature
networks (svg files) using lv_com and the lung-TSLCs concordant gene signatures as
inputs in the IPA were extracted, parsed, and compiled41. Please visit the
supplementary website for the Perl script and R code. Correlated output genes
generated from the IPA as well as the input genes were further mapped onto the
human PPIs downloaded from the NCBI (HPRD, BioGrid, and BIND). PPIs would
be retrieved if and only if both of the reactants were queried. Then, IPA generated
networks were merged with the mapped human PPIs. To consolidate the network
models, we calculated the co-expression Pearson correlation coefficients (PCCs) of
every gene-gene interactions in the merged networks using all TSLCs and the lung
TSLC only. Absolute values of PCCs of co-expression were calculated using all TSLCs
and 0.4 was set as the cut-off threshold for the consensus TSLC networks. For the
lung-TSLC networks, we set the cut-off threshold of abs(PCCs in lung TSLCs).0.8.
The thresholds were determined such that the number of nodes in the final networks
would be less than 100. Functional annotation clustering of genes in the TSLC-
consensus networks was analyzed by DAVID (Database for Annotation Visualization
and Integrated Discovery, NIH)42.
Network topological analysis and predictive measurements derived from signal
processingmechanics. Network topological analyses and classification of genes were
performed according to methods previously published41. We developed five
measurements to describe the network signal processing mechanics: expression level
(Exprs); topologically weighted expression level (wt.Exprs); the 0-order magnitude
(Mag), i.e. amplitude of the transcriptional signal; the 1-order property spectrum
(Spec), i.e. the pair-wise relative transcriptional noise; and the signal-to-noise ratio
(SNR). In the networkmodel, there would beNiweighting genes as well asNjmember
genes of scalable sizes. For each gene, g, we assigned a measure of topological
property, wtg. Importantly, wtg would be different according to the topological
grouping: that is, zero for the periphery genes; degrees (number of nodes connected)
for the intra-modular hubs; and either degrees or the estimated effects of perturbation
(focality)41 for the inter-modular hubs. Then, for a single weighting gene, g, in the
model with Nj member genes, the expression value (Exprs) was hg; wt.Exprs was the
value of wtg*hg; Mag would be m gð Þ~wtg  abs hg
 
; Spec would be calculated as
s gð Þ~ 1
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SNR would be defined as x gð Þ~m gð Þ=s gð Þ. For a group
of Ni weighting genes, Exprs, wt.Exprs, and Mag would
be the averaged values. Spec would be calculated as
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and SNR unchanged.
Statistical and survival analyses. Student t test and bootstrap Kolmogorov-Smirnov
test were used to determine the statistical significance of means or distributions.
Kaplan-Meier survival curves based on quartiles of network-based predictive mea-
surements were tested by log-rank tests. We also fitted Cox proportional hazard
regression model and used Wald test statistics to determine a trend of gene dosage
effects. Statistical significance was set at P , 0.05. Please visit the supplementary
website for R codes used in the survival analysis.
Clonogenic assay. For a clonogenic assay, cells were exposed to different
chemotherapeutic agents (cisplatin, doxorubicin, and taxol)(10 mg/ml). After
incubation for 10 days, colonies (.50 cells per colony) were fixed and stained for
20 min with a solution containing crystal violet and methanol. Cell survival was
determined by a colony formation assay. The plating efficiency (PE) and survival
fraction (SF) were calculated as follows: PE 5 (colony number/number of inoculated
cells) 3 100%. SF 5 colonies counted/(cells seeded x (PE/100)).
Western blot assay. Fifteen microliters of sample were boiled at 95uC for 5 min and
separated by 10% SDS-PAGE. The proteins were transferred to Hybond-ECL
nitrocellulose paper (Amersham) by a wet-transfer system. The primary antibodies
used was antibody rabbit anti-human CBX5 (Cell Signaling Technology). The
reactive protein bands were detected by the ECL detection system (Amersham).
In vitro cell invasion analysis and soft agar assay. The 24-well plate TranswellH
system with a polycarbonate filter membrane was used (8 mm pore size; Corning,
United Kingdom). Cell suspensions were seeded in the upper compartment of the
Transwell chamber at a density of 13105 cells in 100 mL of serum-free medium. The
opposite surface of the filter membrane facing the lower chamber was stained with
Hoechst33342 for 3 min, and migrating cells were visualized under an inverted
microscope. For the soft agar assay, the bottom of each well (35 mm) of a six-well
culture dish was coated with 2 mL of an agar mixture (DMEM, 10%(v/v) FCS, 0.6%
(w/v) agar). After the bottom layer solidified, 2 mL of a top agar-medium mixture
(DMEM, 10%(v/v) FCS, 0.3%(w/v) agar) containing 23104 cells was added and
incubated at 37uC for 4weeks. The plates were stainedwith crystal violet. The number
of colonies was counted using a dissecting microscope.
Quantitative real-time RT-PCR and patients and tissue samples. Lung
adenocarcinomas (LACs) and adjacent noncancerous tissues were obtained at the
time of surgery from 20 patients in Taipei Veterans General Hospital. All patients
gave their informed consent under institution’s approval. Total RNA was extracted
from tissue samples using TRIzol according to the manufacturer’s protocol
(Invitrogen, Carlsbad, CA). The amplification and PCR reaction were carried out
(Roche, Alameda, CA). Standard curves (cycle threshold values versus template
concentration) were prepared for each target gene and for the endogenous reference
(GAPDH) in each sample.
Patient subjects and immunohistochemistry (IHC). Between 1996 and 2009, 125
patients with operable LAC, without histories of radiation or chemotherapy,
underwent surgery at Taipei Veterans General Hospital (Table S6). All samples were
obtained after informed consent according to the tenets of the Declaration of
Helsinki. Tissue samples were spotted on glass slides for IHC staining, deparaffinised,
rehydrated, processed with antigen retrieval by 1X Trilogy diluted in H2O
(Biogenics), immersed in 3% H2O2 for 10 min, and washed with PBS 3 times. The
tissue sections were then blocked with serum (Vestastain Elite ABC kit, Vector
Laboratories, Burlingame, CA) for 30 min, followed by incubating with the primary
antibody rabbit anti-human CBX5 (Cell Signaling Technology) in PBS solution at
room temperature for 2 hr, washed with PBS 3 times, incubated with biotin-labeled
secondary antibody for 30 min, incubated with streptavidin-horse radish peroxidase
conjugates for 30 min, washed with PBS 3 times, and immersed with chromogen 3-
39-diaminobenzidine plus H2O2 substrate solution (VectorH DBA/Ni substrate kit,
SK-4100, Vector Laboratories, Burlingame, CA) for 10 min. Hematoxylin was
applied for counter-staining (Sigma Chemical Co., USA). Study pathologists, blinded
to the clinical data, examined and scored the IHC staining. The interpretation was
done in five high-power views for each slide, and 100 cells per view were counted for
analysis.
Xenograft tumorigenicity assay. All procedures involving animals were in
accordance with the institutional animal welfare guideline and the experiment was
approved by Taipei Veterans General Hospital. Virus-infected lung TSLCs were
harvested, washed with PBS, and re-suspended in normal culture medium. Lung
TSLC cells (23105) infected with sh-CBX5 RNAi or control vector were injected
through tail vein of 8-week-old male NOD-SCID mice. All mice were anesthetized
and killed on day 56 (8 weeks) after injection. The number of tumor nodules and
tumor volume in lung of the transplanted mice were measured by ex vivo and H&E
survey. Ionizing radiation (IR) was delivered by a cobalt unit (Theratronic
International, Inc., Ottawa, Canada) at a dose rate of 1.1 Gy/min (source-to-surface
distance 5 57.5 cm). Lung CD1331-TSLCs treated with sh-CBX5 RNAi were
exposed to the radiation doses of 2, 4, 6, 8, and 10 Gy.
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